Analysing Functional Outcomes in Post-Operative Glioblastoma Patients
Research type
Research Study
Full title
Analysing Functional Outcomes in Post-Operative Glioblastoma Patients: a Prospective Single Centre Cohort Study
IRAS ID
315391
Contact name
Emily Rose Bligh
Contact email
Sponsor organisation
NHS Greater Glasgow & Clyde
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Background
Glioblastoma is the most common malignant primary brain tumour in adults (20%). It has a median overall survival (OS) of 12-15 months and is a progressive disease which causes substantial debilitating symptoms from impaired neurological functioning. Recent endeavours to improve survival are focused on individualised surgical, oncological and palliative management, i.e. precision medicine, but a holistic approach to manage overall functional and behavioural dynamics is needed. Some patients though having a long overall survival can have a poor and prolonged functional outcome. The endpoint of death does not explain the holistic nature of this disease and its impact on an individual. Patient reported outcomes (PROs) offer validated and reliable data on quality of life (QoL) in addition to wellbeing, symptom activity and neurological assessment. A recent review has proposed a five-facet approach to functional outcome metrics in glioblastoma patients including activities of daily living (ADLs), wellbeing, seizure activity, neurological and neurocognitive assessment. The proposed prospective study shall provide an analysis in our neurosurgical and neurooncological units to provide an insight into potential measurable benefits and risks of current glioblastoma treatment regimens beyond overall survival. This would help guide future research into patient centred functional measures.
Primary Objectives
Describe and analyse functional outcomes in adult glioblastoma patients.
Methods
Single centre prospective cohort study. Patients aged 18 years and older having a tissue proven diagnosis of a glioblastoma during a 6-month period. The intended start date is 3rd October 2022 and proposed end date is 3rd April 2023. Data will be retrieved through clinical documents and voluntary patient surveys. Patient questionnaires will be undertaken around diagnosis, at 3-months and 6-months Functional outcomes will be measured through activities of daily living (ADLs), wellbeing, seizure activity, neurological and neurocognitive assessment using standardized and validated collection tools and a short additional survey suggested by PPI.REC name
Yorkshire & The Humber - Leeds East Research Ethics Committee
REC reference
22/YH/0214
Date of REC Opinion
4 Nov 2022
REC opinion
Further Information Favourable Opinion